Avior Wealth Management LLC Boosts Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Avior Wealth Management LLC grew its position in Illumina, Inc. (NASDAQ:ILMN) by 12.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,745 shares of the life sciences company’s stock after purchasing an additional 418 shares during the period. Avior Wealth Management LLC’s holdings in Illumina were worth $521,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in Illumina in the 3rd quarter valued at about $30,000. State of Wyoming bought a new position in shares of Illumina in the second quarter valued at approximately $32,000. VisionPoint Advisory Group LLC increased its position in shares of Illumina by 344.6% during the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after acquiring an additional 193 shares during the last quarter. Riverview Trust Co lifted its holdings in Illumina by 203.5% during the third quarter. Riverview Trust Co now owns 261 shares of the life sciences company’s stock worth $36,000 after acquiring an additional 175 shares during the period. Finally, Gradient Investments LLC lifted its holdings in Illumina by 375.0% during the fourth quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock worth $40,000 after acquiring an additional 225 shares during the period. 89.42% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Illumina news, CEO Jacob Thaysen bought 7,330 shares of Illumina stock in a transaction that occurred on Thursday, February 22nd. The stock was acquired at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the transaction, the chief executive officer now directly owns 14,861 shares in the company, valued at $2,010,544.69. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.17% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on ILMN shares. HSBC lowered Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Barclays boosted their target price on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research note on Wednesday, April 10th. Stephens reaffirmed an “overweight” rating and issued a $170.00 price target on shares of Illumina in a report on Wednesday, April 10th. OTR Global reiterated a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. Finally, TD Cowen downgraded Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 target price for the company. in a research report on Thursday, January 4th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $167.70.

Illumina Stock Down 1.4 %

Shares of ILMN opened at $116.69 on Friday. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $232.23. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.26. The business’s 50-day moving average price is $133.78 and its 200-day moving average price is $128.07.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The company had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter in the previous year, the company earned $0.14 earnings per share. Illumina’s revenue for the quarter was up 3.6% on a year-over-year basis. On average, analysts predict that Illumina, Inc. will post 0.91 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.